In what has been a down year for mergers and acquisitions deals, Amgen made headlines late last year by announcing it will acquire Horizon for
As the recent rise of pre-clinical initial public offerings (IPOs) indicates, investors in the life sciences no longer need to see an actual treatment to
So you are worried about your pipeline? That’s totally valid. 90% of clinical drug candidates fail in clinical trials. Compounding the problem, drug development is
In the life science industry, product development has evolved into a costly endeavor. Translational tools seek to change this. Despite the promise of a novel
